Latest news with #Veklury
Yahoo
25-04-2025
- Business
- Yahoo
Why Gilead Sciences Stock Slipped Today
Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its share price decline in excess of 2% the following day. That contrasted unfavorably with the 0.6% rise of the S&P 500 index that trading session. For the period, Gilead's revenue clocked in at $6.67 billion, essentially flat over the same quarter of 2024. The company attributed this to sales declines of COVID drug Veklury and oncology products. This was offset by improvements in liver disease and human immunodeficiency virus (HIV) medications. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » As for profitability, Gilead flipped to a non-GAAP (adjusted) net income of just under $2.3 billion, or $1.81 per share, from the year-ago loss of $1.6 billion. The first quarter 2024 result was affected by the acquisition of liver disease drug developer CymaBay Therapeutics, the company said, plus a $2.4 billion impairment related to a 2020 deal for a peer, Immunomedics. This meant a mixed quarter for Gilead. On average, analysts were modeling $6.78 billion for revenue, but anticipating a lower per-share adjusted profit of $1.77. Gilead also made an adjustment to its existing, full-year guidance that made some investors unhappy. For the entirety of 2025 it's expecting headline earnings per share to land at $5.65 to $6.05, where previously it had forecast $5.95 to $6.35. However, it left its adjusted profitability estimate unchanged at $7.70 to $8.10 per share. Revenue is still expected to come in at $28.2 billion to $28.6 billion. Before you buy stock in Gilead Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Gilead Sciences wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $591,533!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $652,319!* Now, it's worth noting Stock Advisor's total average return is 859% — a market-crushing outperformance compared to 158% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Gilead Sciences. The Motley Fool has a disclosure policy. Why Gilead Sciences Stock Slipped Today was originally published by The Motley Fool
Yahoo
12-02-2025
- Business
- Yahoo
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025. Adjusted earnings per share (EPS) of $1.90 beat the Zacks Consensus Estimate of $1.67. In the year-ago quarter, the company reported EPS of $1.72. The year-over-year increase in EPS was driven by higher product sales and lower acquired IPR&D expenses. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. Total revenues of $7.6 billion comfortably beat the Zacks Consensus Estimate of $7.1 billion. Revenues also increased 6% year over year, primarily due to higher HIV, oncology and liver disease drug sales. The stock was up 4% in after-market trading on Feb. 11 in response to better-than-expected quarterly results and encouraging guidance for 2025. The stock is also up in pre-market trading today. Gilead's shares have surged 34.8% in the past year against the industry's decline of 11.7%. Image Source: Zacks Investment Research Total product sales rose 7% year over year to $7.5 billion. Excluding Veklury, product sales increased 13% to $7.2 billion. HIV product sales grew 16% year over year to $5.5 billion, primarily driven by higher demand, higher average realized price and favorable inventory dynamics. The figure beat both the Zacks Consensus Estimate and our model estimate of $5 billion. Flagship HIV therapy Biktarvy's sales increased 21% year over year to $3.8 billion, driven by higher demand, favorable inventory dynamics and higher average realized price. The reported number beat both the Zacks Consensus Estimate and our model estimate of $3.5 billion. Per GILD, Biktarvy accounts for over 50% share of the treatment market in the United States. Descovy (FTC 200 mg/TAF 25 mg) sales increased 21% year over year to $616 million, driven by higher demand and average realized price. The reported number beat the Zacks Consensus Estimate of $574 million and our model estimate of $558.5 million. Descovy maintained over 40% U.S. market share in pre-exposure prophylaxis (PrEP). The Liver Disease portfolio sales, which include chronic HCV, chronic hepatitis B virus (HBV) and chronic hepatitis delta virus (HDV), increased 4% to $719 million. The increase was driven by higher demand for HBV and HDV drugs, along with incremental sales of Livdelzi (seladelpar) in primary biliary cholangitis (PBC). Veklury sales plunged 53% to $337 million, primarily due to lower rates of COVID-19-related hospitalizations, particularly in the United States. Sales missed the Zacks Consensus Estimate of $338 million and our model estimate of $342 million. Cell Therapy product (comprising Yescarta and Tecartus) sales increased 5% to $488 million. The figure beat the Zacks Consensus Estimate of $480 million and our model estimate of $482 million. Yescarta sales increased 6% year over year to $390 million, primarily driven by higher average realized price and increased demand outside the United States, partially offset by lower demand in the country. Tecartus (adult acute lymphoblastic leukemia) sales were flat year over year at $98 million, as increased demand outside the United States was offset by lower demand in the country. Breast cancer drug Trodelvy's sales increased 19% year over year to $355 million, primarily driven by higher demand in all regions. Trodelvy's sales beat the Zacks Consensus Estimate of $282 million and our model estimate of $298.6 million. Adjusted product gross margin increased to 86.7% from 86.1% in the year-ago quarter due to product mix. Research and development expenses totaled $1.6 billion, up from $1.5 billion in the year-ago quarter due to incremental investments and clinical activities across its portfolio. SG&A expenses amounted to $1.9 billion, up 16%, driven by litigation accrual and higher sales and marketing spending. This can be attributed to launch preparation activities for lenacapavir for the investigational use of HIV PrEP and Livdelzi. Revenues in 2024 increased 6% to $28.8 billion due to higher sales in HIV, oncology and liver disease. The reported number surpassed the Zacks Consensus Estimate of $28.2 billion. EPS of $4.62 was down 31% from $6.72 in 2023 due to higher acquired IPR&D expenses related to the CymaBay acquisition and higher income tax expenses. The reported number, however, surpassed the Zacks Consensus Estimate of $4.36. Product sales are projected to be between $28.2 billion and $28.6 billion. The Zacks Consensus Estimate for the metric is pegged at $28.3 billion. Total product sales, excluding Veklury, are expected to be between $26.8 billion and $27.2 billion. Total Veklury sales are estimated to be $1.4 billion. Adjusted EPS is anticipated to be in the range of $7.70-$8.10. The Zacks Consensus Estimate for the same is pegged at $7.59. The FDA granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with extensive-stage small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use recommended approval of seladelpar for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone or as monotherapy in those unable to tolerate UDCA. Gilead submitted a new drug application to the FDA and marketing authorization application and an EU-Medicines for All application to the EMA for approval of twice-yearly lenacapavir for HIV prevention. Gilead announced that its board has declared an increase of 2.6% in its quarterly cash dividend, beginning the first quarter of 2025. The increase will result in a quarterly dividend of $0.79 per share of common stock. Gilead's fourth-quarter results were highly impressive as HIV growth driver Biktarvy maintained its dominant position across major markets. Descovy, too, put up a strong performance. Gilead Sciences, Inc. Price, Consensus and EPS Surprise Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote Biktarvy sales increased 13% to $13.4 billion in 2024. Given the strong data from the phase III PURPOSE 1 and PURPOSE2 trials, a potential approval of lenacapavir is in the cards that should further solidify GILD's robust HIV franchise. Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach a larger number of people who could benefit from a prevention regimen. Approval of better HIV treatments should strengthen the HIV franchise in the wake of increasing competition from the likes of GSK plc GSK. GSK posted 13% growth in HIV sales in 2024, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato. However, total revenues in 2025 are likely to be impacted by approximately $1.1 billion as a result of the new Medicare Part D model. HIV revenues might be impacted by $900 million. Consequently, GILD expects HIV revenues to remain roughly flat in 2025. The FDA approval of Livdelzi for PBC strengthens GILD's liver disease portfolio. Seladelpar was added to GILD's portfolio/pipeline through the acquisition of CymaBay Therapeutics Inc. for $4.3 billion in March 2024. A potential approval in the EU should boost sales. Gilead currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the biotech sector are Immunocore Holdings plc IMCR and Alnylam Pharmaceuticals ALNY. While IMCR sports a Zacks Rank #1 (Strong Buy) at present, ALNY carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 90 days, estimates for Immunocore's 2024 loss per share have remained unchanged at 94 cents. Loss per share estimates for 2025 have narrowed from $1.66 to $1.62 in the past seven days. IMCR's earnings beat estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 25.57%. In the past 30 days, estimates for Alnylam Pharmaceuticals' 2024 loss per share have remained constant at 39 cents. The consensus estimate for 2025 earnings per share is currently pegged at 41 cents. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report To read this article on click here. Zacks Investment Research Sign in to access your portfolio
Yahoo
12-02-2025
- Business
- Yahoo
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Gilead Sciences (GILD) reported $7.57 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.4%. EPS of $1.90 for the same period compares to $1.72 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $7.06 billion, representing a surprise of +7.27%. The company delivered an EPS surprise of +13.77%, with the consensus EPS estimate being $1.67. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- Veklury- U.S. $108 million versus the three-analyst average estimate of $160.11 million. The reported number represents a year-over-year change of -70.3%. Product Sales- Oncology- Trodelvy- U.S. $247 million versus $237.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.3% change. Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S. $185 million versus $202.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.4% change. Product Sales- HIV- Symtuza-Revenue share- U.S. $112 million versus the three-analyst average estimate of $109.94 million. The reported number represents a year-over-year change of +7.7%. Total product sales- Total: $7.54 billion versus $7.06 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change. Revenues- Royalty contract and other revenues: $33 million versus the eight-analyst average estimate of $49.91 million. The reported number represents a year-over-year change of -26.7%. Product Sales- Oncology- Cell Therapy- Yescarta- Total: $390 million versus $386.44 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +6% change. Product Sales- HIV- Biktarvy- Total: $3.77 billion versus the seven-analyst average estimate of $3.46 billion. The reported number represents a year-over-year change of +21.4%. Product Sales- HIV- Odefsey- Total: $336 million compared to the $314.11 million average estimate based on seven analysts. The reported number represents a change of -1.2% year over year. Product Sales- HIV- Genvoya- Total: $470 million versus the seven-analyst average estimate of $482.51 million. The reported number represents a year-over-year change of -9.1%. Product Sales- HIV- Descovy- Total: $616 million compared to the $573.59 million average estimate based on seven analysts. The reported number represents a change of +21% year over year. Product Sales- Oncology- Trodelvy- Total: $355 million versus the seven-analyst average estimate of $281.97 million. The reported number represents a year-over-year change of +18.7%. View all Key Company Metrics for Gilead here>>>Shares of Gilead have returned +6.2% over the past month versus the Zacks S&P 500 composite's +4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report To read this article on click here. Zacks Investment Research
Reuters
11-02-2025
- Business
- Reuters
Gilead quarterly results beat estimates
Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% and acquisition-related costs fell. The California-based drugmaker's adjusted profit rose to $1.90 per share from $1.72 a year earlier, beating analysts' estimates of $1.70 per share, according to LSEG data. Revenue for the quarter rose 6% to $7.57 billion, also exceeding Wall Street estimates of $7.14 billion. Net earnings per share rose to $1.42 from $1.14 a year ago. For 2025, the company said it expects adjusted earnings of $7.70 to $8.10 per share on product sales of $28.2 billion to $28.6 billion. The low end of the company earnings range is above analysts' projections of $7.58 per share. They are estimating 2025 revenue of $28.42 billion. "From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PreP (pre-exposure prophylaxis) in summer 2025," Gilead CEO Daniel O'Day said in a statement. The U.S. Food and Drug Administration is expected to decide by mid-year whether to approve lenacapavir as a twice-yearly injection to prevent HIV infection. Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher demand, higher prices and favorable inventory dynamics. Biktarvy sales rose 21% to $3.8 billion, beating the average analyst estimate of $3.48 billion. Sales of COVID-19 drug Veklury fell 53% to $337 million, which was short of Wall Street expectations of $397 million. Oncology sales rose 10% to $843 million and sales of liver disease drugs rose 4% to $719 million. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
